Alterity Therapeutics (ATHE) Depreciation & Amortization (CF) (2009 - 2025)
Alterity Therapeutics (ATHE) posted quarterly Depreciation & Amortization (CF) of -$78768.1 for Q4 2025, little changed year-on-year from -$78824.6 in Q4 2024, and little changed on a QoQ basis from -$78711.6 in Q4 2024.
Alterity Therapeutics (ATHE) Depreciation & Amortization (CF) (2009 - 2025) Analysis & Trends
Alterity Therapeutics (ATHE) has reported Depreciation & Amortization (CF) for 14 consecutive years, with -$78768.1 the latest figure, recorded in Q4 2025.
- Quarterly Depreciation & Amortization (CF) changed 0.07% year-over-year to -$78768.1 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$157479.6 (changed 0.18% YoY) and the FY2025 annual result came in at $78679.1, down 100.0% from the prior year.
- Depreciation & Amortization (CF) was little changed at -$78768.1 in Q4 2025 per ATHE's latest filing, from -$78711.6 in the prior quarter.
- Over the last five years, Depreciation & Amortization (CF) for ATHE reached as high as -$35218.0 in Q4 2021 and fell as low as -$78768.1 in Q4 2025.
- A 5-year average of -$62801.5 and a median of -$78478.5 in 2023 frame the typical range for Depreciation & Amortization (CF).
- Annual changes were most pronounced in 2023 — Depreciation & Amortization (CF) sank 83.23% — and 2025, when it declined 0.07%.
- Year by year, Depreciation & Amortization (CF) stood at -$35218.0 in 2021, then dropped by 21.62% to -$42831.1 in 2022, then plunged by 83.23% to -$78478.5 in 2023, then declined by 0.3% to -$78711.6 in 2024, then retreated by 0.07% to -$78768.1 in 2025.
- According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered -$78768.1, -$78711.6, and -$78478.5 for Q4 2025, Q4 2024, and Q4 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 41.14 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 91,781.47 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.20 Mn |
| 10 | Alterity Therapeutics | 30.00 Bn | 30.00 Bn | - | -78,768.06 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -78,768.06 |
| Dec 31, 2025 | -78,768.06 |
| Dec 31, 2024 | -78,711.56 |
| Dec 31, 2024 | -78,711.56 |
| Dec 31, 2023 | -78,478.51 |
| Dec 31, 2023 | -78,478.51 |
| Dec 31, 2022 | -42,831.11 |
| Dec 31, 2022 | -42,831.11 |
| Dec 31, 2021 | -35,218.01 |
| Dec 31, 2021 | -35,218.01 |
| Jun 30, 2020 | 61,045.35 |
| Jun 30, 2020 | 61,045.35 |
| Dec 31, 2019 | -40,408.06 |
| Dec 31, 2019 | -40,408.06 |
| Jun 30, 2019 | 20,972.05 |
| Jun 30, 2019 | 20,972.05 |
| Dec 31, 2018 | 10,363.85 |
| Dec 31, 2018 | 10,363.85 |
| Jun 30, 2018 | 153.95 |
| Jun 30, 2018 | 153.95 |